NasdaqGS:BNTXBiotechs
Is BioNTech (BNTX) Priced Too Richly For Its Lung Cancer Promise?
BioNTech stock has rebounded over the past year, yet the share price still screens as expensive on broad valuation checks after a steep 65.0% decline over five years. Recent lung cancer trial progress has put the spotlight back on the company, while the current pricing leaves investors weighing opportunity against what they are being asked to pay.
Over the past 5 years, BioNTech has delivered a total return that declined 65.0%, which puts the recent recovery in a much longer period of weak...